Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 15/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 13/20 | 0.49 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26695558 | 1.00 | CYP11B2 (0.50) | CYP11B2CYP11B1EGLN2KDM4EALDH1A1 | |
| SCHEMBL26695705 | 0.87 | CYP11B2 (0.50) | CYP11B2CYP11B1EGLN2 | |
| SCHEMBL15638116 | 0.84 | CYP11B2 (0.62) | CYP11B2CYP11B1EGLN2 | |
| SCHEMBL15638514 | 0.80 | KDM4E (0.61) | KDM4EALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL30711925 | 0.76 | CYP11B2 (0.57) | CYP11B2CYP11B1EGLN2 | |
| SCHEMBL30711935 | 0.76 | KDM4E (0.56) | CYP11B2CYP11B1EGLN2KDM4EALDH1A1 | |
| SCHEMBL16936423 | 0.74 | KDM4E (0.54) | KDM4EALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL1162716 | 0.74 | KDM4E (0.50) | KDM4EALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL1702791 | 0.74 | KDM4E (0.50) | CYP11B2CYP11B1KDM4EALDH1A1GAA | |
| SCHEMBL16681058 | 0.73 | ALDH1A1 (0.59) | KDM4EALDH1A1GAASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| CN-119173510-A | Hydroxy amide derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2023222115-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | 四川汇宇制药股份有限公司 | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | HDAC1, HDAC11, HDAC5 | CYP11B2 109/4885CYP11B1 135/4885EGLN2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.